146 / 172
146
32. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM,
Walker D, et al. Effect of the early use of the anti-tumor
necrosis factor adalimumab on the prevention of job loss in
patients with early rheumatoid arthritis. Arthritis Rheum
2008 ;59:1467-74.
33. Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus
methotrexate improved SF-36 scores and reduced the effect of
rheumatoid arthritis (RA) on work activity for patients with
early RA. J Rheumatol
2008;35:206-15.
34.van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman
MH. Improvement
in
work
place
and
household
productivity for patients with early rheumatoid arthritis
treated with adalimumab plus methotrexate: work outcomes
and their correlations with clinical and radiographic measures
from a randomized controlled trial companion study. Arthritis
Care Res (Hoboken) 2010;62:226-34.
35. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara
CA, Compagnone D, et al. Adalimumab, a fully human anti
tumor necrosis factor-alpha monoclonal antibody, and
concomitant standard antirheumatic therapy for the treatment
of rheumatoid arthritis: results of STAR (Safety Trial of
Adalimumab in Rheumatoid Arthritis). J Rheumatol
2003;30:2563-71.
36. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K,
Valesini G, Hensor EM, et al. Current evidence for the
management of rheumatoid arthritis with biological disease-
modifying antirheumatic drugs: a systematic literature review
informing the EULAR recommendations for the management
of RA. Ann Rheum Dis 2010;69:976-86.
37. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E,
Richard L, et al. Effect of certolizumab pegol with
methotrexate on home and work place productivity and social
activities in patients with active rheumatoid arthritis. Arthritis
Rheum 2009;61:1592-600.